Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?
Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter